Datametrex AI Limited (TSXV:DM) (the “Company” or “Datametrex”) is pleased to announce its agreement to partner with EMPOWER CLINICS INC. (CSE: EPW) (“Empower”) through its subsidiary Canntop AI Inc. (“Canntop”) on the creation of a pilot program (“Pilot”) using Artificial Intelligence (“AI”) to analyze and gain insights about Empower patient data, physician treatment recommendations and overall long-term efficacy of patient care.
Datametrex AI Limited (TSXV:DM) (the “Company” or “Datametrex”) is pleased to announce its agreement to partner with EMPOWER CLINICS INC. (CSE: EPW) (“Empower”) through its subsidiary Canntop AI Inc. (“Canntop”) on the creation of a pilot program (“Pilot”) using Artificial Intelligence (“AI”) to analyze and gain insights about Empower patient data, physician treatment recommendations and overall long-term efficacy of patient care. This is to identify improvements and efficacy in long-term patient care.
Empower intends to use Canntop’s AI platform to gain actionable insights on how consumer social data is generating nationwide interest in CBD based products, alternative pain management options and the use of cannabis-based therapies.
The initial pilot will utilize Empower patient data in a HIPAA compliant manner, to determine if normalized data can be generated using Datametrex AI solutions to understand how patient care and efficacy of physician guided treatment recommendations are positively impacting serious qualifying conditions of patients.
“We believe using AI tools to analyze the substantial amounts of data in the Empower database and the additional data from the recently announced proposed Sun Valley acquisition can make Empower a data science leader in the Cannabis industry,” said Steven McAuley, Empower’s Chairman & CEO. He further states, “The outcomes of our AI efforts with Datametrex are definitely going to position the Company as an educational leader and we plan to collaborate with the industry to ultimately improve patient care.”
“Datametrex has already utilized its Nexalogy AI solution for Health Canada studies in the Cannabis sector to understand consumer usage and patterns based on massive social insights generated through social media channels,” said Jeffrey Stevens, Datametrex President & COO. “We believe an AI pilot with Empower has the potential to provide disruptive insights that alternative care options can provide people around the world.”
Empower is undertaking new growth initiatives to be positioned as a vertically integrated diverse health and wellness company with an expanding network of physician-staffed clinics, a diverse CBD product strategy and a leader in hemp-derived CBD extraction, research and development. Treatment solutions are focused on education, data and efficacy in combination with other modalities to support patients with serious qualifying conditions, such as chronic pain, PTSD, sleep disorders, opioid dependency, epilepsy and more. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based product options in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine and an expanded product development strategy, Empower is ready to capitalize on the explosive growth expectations in the United States after the passing of US$867 billion Agriculture Improvement Act (the Farm Bill).
Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiaries, Nexalogy (www.nexalogy.com) and Canntop AI (www.canntop.com) and Implementing Blockchain technology for secure Data Transfers through its investee company, Graph Blockchain (www.graphblockchain.com).
Additional information on Datametrex is available at: www.datametrex.com
For further information, please contact:
Jeffrey Stevens – President & COO
Phone: (647) 400-8494
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation, those discussed in the Company’s current MD&A and Annual Information Form, both of which have been filed on SEDAR and can be accessed at www.sedar.com.
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.